Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor
Aclaris reported positive full Phase 1a results for ATI-052, showing an estimated half-life of 45 days that supports dosing every three months and robust inhibition of inflammatory biomarkers. The company plans to initiate a Phase 2b program for ATI-052 in asthma by Q4 2026, with top-line Phase 1b results in asthma and atopic dermatitis expected in the second half of this year.
Key figures
- Drug Name
- ATI-052
- Phase Of Trial
- Phase 1a
- Half life days
- 45
- Dosing interval months
- 3
- Market opportunity ati 2138 low usd
- $1.0 billion
- Market opportunity ati 2138 high usd
- $4.0 billion
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.